NDC 0002-8926

LARTRUVO

Olaratumab

LARTRUVO is a Intravenous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Eli Lilly And Company. The primary component is Olaratumab.

Product ID0002-8926_3186948d-039a-4bff-8cca-42bd09c773b9
NDC0002-8926
Product TypeHuman Prescription Drug
Proprietary NameLARTRUVO
Generic NameOlaratumab
Dosage FormInjection, Solution
Route of AdministrationINTRAVENOUS
Marketing Start Date2016-10-19
Marketing CategoryBLA / BLA
Application NumberBLA761038
Labeler NameEli Lilly and Company
Substance NameOLARATUMAB
Active Ingredient Strength10 mg/mL
NDC Exclude FlagN
Listing Certified Through2019-12-31

Packaging

NDC 0002-8926-01

1 VIAL, SINGLE-USE in 1 CARTON (0002-8926-01) > 50 mL in 1 VIAL, SINGLE-USE
Marketing Start Date2016-10-19
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 0002-8926-01 [00002892601]

LARTRUVO INJECTION, SOLUTION
Marketing CategoryBLA
Application NumberBLA761038
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitML
Marketing Start Date2016-10-19
Marketing End Date2020-11-27

Drug Details

Active Ingredients

IngredientStrength
OLARATUMAB10 mg/mL

OpenFDA Data

SPL SET ID:6a5bff43-f922-46ae-a727-d54d9138c46e
Manufacturer
UNII
RxNorm Concept Unique ID - RxCUI
  • 1855744
  • 1855739
  • 1872478
  • 1872479
  • NDC Crossover Matching brand name "LARTRUVO" or generic name "Olaratumab"

    NDCBrand NameGeneric Name
    0002-7190LARTRUVOolaratumab
    0002-8926LARTRUVOolaratumab

    Trademark Results [LARTRUVO]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    LARTRUVO
    LARTRUVO
    86842906 5536174 Live/Registered
    Eli Lilly and Company
    2015-12-08
    LARTRUVO
    LARTRUVO
    86430008 5453832 Live/Registered
    Eli Lilly and Company
    2014-10-21

    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.